Skip to main content

Flagship Communities Real Estate Investment Trust Expands Presence in Ohio

Not for distribution to U.S. newswire services or dissemination in the United States. TORONTO, May 12, 2026 (GLOBE NEWSWIRE) — Flagship Communities Real Estate Investment Trust (TSX:MHC.U) (TSX:MHC.UN) (“Flagship” or the “REIT”) today announced it expanded its presence in northern Ohio with a strategic acquisition of a manufactured housing community (“MHC”) for total consideration of approximately US$1.5 million (the “Acquisition”). The Acquisition is expected to be immediately accretive to the REIT’s adjusted funds from operations (“AFFO”) on a per Unit basis. The Acquisition is located in Marblehead, Ohio, a resort area along Lake Erie and is comprised of 28 lots that are 100% occupied. The property includes a private beach area and a fishing pier along with a number of boat dock slips and is in close proximity to another Flagship-owned...

Continue reading

Form 8.3 – [ANIMALCARE GROUP PLC – 11 05 2026] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree ANIMALCARE GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position...

Continue reading

Form 8.3 – [ADVANCED MEDICAL SOLUTIONS GROUP PLC – 11 05 2026] – (CGAML)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY ASSET MANAGEMENT LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree ADVANCED MEDICAL SOLUTIONS GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date...

Continue reading

Diana Shipping Inc. Launches Campaign Website in Connection with Effort to Unlock Immediate Value at Genco Shipping & Trading

Visit www.CashforGenco.com for Details on Genco Board and Management’s Pattern of Entrenchment and Extensive Governance Failures at the Expense of Shareholders Provides Information Regarding Diana’s Highly Qualified Independent Nominees and Materials Related to Diana’s Proxy Campaign Diana Urges Genco Shareholders to Vote the GOLD Universal Proxy Card “FOR” Diana’s Six Independent Director Nominees at the 2026 Annual Meeting ATHENS, Greece, May 12, 2026 (GLOBE NEWSWIRE) — Diana Shipping Inc. (NYSE: DSX) (“Diana” or “the Company”), a global shipping company specializing in the ownership and bareboat charter-in of dry bulk vessels that owns approximately 14.7% of the outstanding shares of common stock of Genco Shipping & Trading Limited (NYSE: GNK) (“Genco”), today announced the launch of www.CashforGenco.com, a campaign...

Continue reading

Humacyte Appoints Dr. Todd E. Rasmussen as Chief Surgical Officer

– Distinguished vascular surgeon brings decades of clinical experience, innovation, and leadership to new role at cutting-edge biotech manufacturer – – Appointment brings important surgical experience and perspective to Humacyte’s corporate leadership team as clinical adoption of Symvess® ramps up and pipeline indications move toward planned approval – DURHAM, N.C., May 12, 2026 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that Todd E. Rasmussen, M.D., has joined the company as Chief Surgical Officer. In this role, Dr. Rasmussen will focus on providing peer-to-peer scientific support, medical education, and technical insights to surgeons and other healthcare...

Continue reading

Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive

Second Positive DSMB Review Supports Continued Study Progress Interim Phase 3 Results Support Ovaprene’s Differentiation as a First-in-Category, Hormone-Free, Intravaginal Monthly Contraceptive SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced positive interim safety and efficacy results from its ongoing Phase 3 clinical trial evaluating the contraceptive effectiveness, safety and acceptability of Ovaprene®, the company’s investigational monthly, hormone-free intravaginal contraceptive. There currently are no FDA-approved, hormone-free, monthly intravaginal contraceptives. The trial’s independent Data Safety Monitoring Board (DSMB) conducted...

Continue reading

SONORO GOLD ANNOUNCES LETTERS OF INTENT TO ACQUIRE ADJACENT MINERAL CONCESSIONS TO FURTHER EXPAND THE CERRO CALICHE GOLD PROJECT

VANCOUVER, Canada, May 12, 2026 (GLOBE NEWSWIRE) — Sonoro Gold Corp. (TSXV: SGO | OTCQB: SMOFF | FRA: 23SP) (“Sonoro” or the “Company”) is pleased to announce that its wholly owned Mexican subsidiary, Minera Mar de Plata (“MMP”), has executed three binding Letters of Intent (the “LOIs”) with two residents of Sonora, Mexico (the “Vendors”) to acquire a 100% interest in 24 mineral concessions, and up to a 51% interest in five additional mineral concessions, located adjacent to the Company’s Cerro Caliche gold project in Sonora, Mexico. The Vendors are at arm’s length to the Company and to its associates and affiliates. Sonoro believes the acquisition is a strategic opportunity to potentially demonstrate the Cerro Caliche project as being part of a larger gold epithermal system, with wide-scale potential to host multiple mineralized...

Continue reading

Rezolve Ai partners with $30bn+ revenue global technology leader Tata Consultancy Services to bring its AI-powered commerce platform to enterprise clients worldwide

TCS to resell Rezolve’s AI-powered commerce platform globally, significantly expanding Rezolve’s route to market through one of the world’s largest digital transformation organizations NEW YORK and MUMBAI, India, May 12, 2026 (GLOBE NEWSWIRE) — Rezolve Ai (NASDAQ: RZLV), a global leader in AI-powered commerce infrastructure, and Tata Consultancy Services (“TCS”), the $30bn+ revenue global IT services, consulting and business solutions leader, today announced a global strategic partnership designed to accelerate the worldwide rollout of agentic commerce. Under the agreement, TCS will resell Rezolve’s AI-powered commerce platform to enterprise clients globally, giving Rezolve access to one of the broadest client relationships, delivery capabilities and digital transformation footprints in the world. The partnership marks a major...

Continue reading

Biometric Identity and Authentication Provider BIO-key to host Q1’26 Investor Webcast Monday, May 18th at 10am ET

HOLMDEL, N.J., May 12, 2026 (GLOBE NEWSWIRE) — BIO-key International, Inc. (NASDAQ: BKYI), a global leader in Identity and Access Management (IAM) and biometric authentication technologies, will host its Q1’26 investor call and webcast on Monday, May 18th at 10 a.m. ET. Mike DePasquale, Chairman & CEO and Cecilia Welch, CFO will lead the call and Q&A session.Call/Webcast Details  Date / Time: Monday, May 18th at 10 a.m. ETCall Dial In #: 1-877-418-5460 U.S. or 1-412-717-9594 Int’lLive Webcast / Replay: Webcast & Replay Link – Available for 3 months.Audio Replay: 1-855-669-9658 U.S. or 1-412-317-0088 Int’l; code 1165470About BIO-key International, Inc. (www.BIO-key.com) BIO-key is revolutionizing authentication and cybersecurity with biometric-centric, multi-factor identity and access management...

Continue reading

Form 8.3 – [ADVANCED MEDICAL SOLUTIONS GROUP PLC – 11 05 2026] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree ADVANCED MEDICAL SOLUTIONS GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.